Results 161 to 170 of about 144,000 (291)

Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy

iNew Medicine, EarlyView.
Therapeutic mechanism, clinical efficacy and future directions for nerandomilast in pulmonary fibrosis. ABSTRACT The recent Phase III FIBRONEER trials establish nerandomilast, a novel oral phosphodiesterase 4B (PDE4B) inhibitor, as an effective therapy for idiopathic and progressive pulmonary fibrosis. By elevating cyclic adenosine monophosphate (cAMP),
Qianwen Bai, Jia Deng, Hongquan Wang, Yao Yao, Tao Wang   +4 more
wiley   +1 more source

Comprehensive assessment of allergic manifestations including drug hypersensitivity in adult patients with inborn errors of immunity. [PDF]

Allergy Asthma Proc
Korkmaz P, Toprak ID, Demir S, Yegit OO, Kahveci N, Hormet Igde M, Celik Kamaci S, Aslan AF, Atasever MD, Eyice Karabacak D, Sezgin ME, Guzel SE, Kaya E, Erden B, Kilinc Z, Imren Aksit IG, Bolek L, Unal D, Gelincik A.   +18 more
europepmc   +1 more source

Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling. [PDF]

Asia Pac Allergy, 2023
Mak HWF, Chan ETS, Yim JSH, Lee E, Lam DLY, Chiang V, Li PH.   +6 more
europepmc   +1 more source

Cellular Responses to Tartrazine and Sulfanilic Acid Exposure in BEAS‐2B Cells: Viability, Apoptosis, and DNA Damage

Journal of Applied Toxicology, EarlyView.
ABSTRACT Tartrazine is a synthetic azo dye widely used in food, pharmaceutical, and cosmetic products, resulting in extensive human exposure, while its toxicity and that of its primary metabolite, sulfanilic acid, remain controversial. Considering the reported association of tartrazine with hypersensitivity and allergic‐like reactions, human bronchial ...
Merve Baysal, Abdullah Burak Karaduman, Büşra Korkut Çelikateş, Merve Güven, Özlem Atlı‐Eklioğlu, Sinem Ilgın   +5 more
wiley   +1 more source

Drug-induced cutaneous hypersensitivity vasculitis [PDF]

Journal of Clinical and Scientific Research, 2016
Harikrishna J, Surekha A, Kalyana Chakravarthy DP, Sreevidya B   +3 more
doaj   +1 more source

Drug hypersensitivity reactions in children in clinical practice: A WAO Statement. [PDF]

World Allergy Organ J
Steering Committee Authors, Berges-Gimeno MP, Alvarez-Cuesta E, Atanaskovic-Markovic M, Attanassi M, Caffareli C, Caubet JC, du Toit G, Guzman-Melendez A, Kuyucu S, Madrigal-Burgaleta R, Mayorga L, Powell E, Ramien M, Gomes ER, Mori F, White AA, Ansotegui IJ, Review Panel Authors, Vivolo Aun M, Barbaud A, Bavbek S, Bernal-Rubio L, Brockow K, Bustamante L, Chang YS, Chiaverini Ensina LF, Cuesta-Herranz J, Fernandes BN, Garvey LH, Giavina-Bianchi P, Kidon MI, Alvarez ML, Makowska JS, Marinho S, Mendoza-Hernández DA, Pagani M, Pino VP, Parisi CAS, Park HS, Peter J, Phillips EJ, Risma K, Solano-Solares E, Tanno LK, Valluzzi RL, Vazquez-Revuelta P, Watts TJ, Yamaguchi M.   +48 more
europepmc   +1 more source

Transgenic murine models for the study of drug hypersensitivity reactions linked to HLA-I molecules. [PDF]

Curr Opin Allergy Clin Immunol, 2023
Puig M, Norcross MA.
europepmc   +1 more source

Exploring the Chemical Complexity and Toxicological Behaviour of Semi‐permanent Make‐Up Pigments: A Systematic Review

Journal of Applied Toxicology, EarlyView.
ABSTRACT Semi‐permanent make‐up (SPMU), or micropigmentation, involves implanting pigments into the dermal layer of the skin for cosmetic enhancement. Unlike topical cosmetics, which are rapidly cleared from the body, SPMU pigments persist in living tissues, raising unique toxicological considerations.
T. A. N. Kaye, M. B. Komane, A. P. Manyisane, R. Manganyi   +3 more
wiley   +1 more source

Management of multiple drug hypersensitivity in a child with very severe aplastic anemia: a case report and therapeutic challenge. [PDF]

Front Pediatr
Chen M, Deng Y, Bin P, Gao R, Liao N, Zhou Z, Huang X, Li J, Wang J.   +8 more
europepmc   +1 more source

Protective Effects of Imeglimin Against Oxaliplatin‐Induced Peripheral Neurotoxicity: Evidence From In Vitro and In Vivo Studies

Journal of Applied Toxicology, EarlyView.
ABSTRACT Oxaliplatin is a platinum‐based anticancer agent widely used for gastrointestinal malignancies; however, it is known to cause dose‐dependent peripheral neuropathy (OIPN), a characteristic adverse effect. OIPN results in a reduced quality of life and often necessitates dose reduction or discontinuation of oxaliplatin; however, effective ...
Yusuke Koura, Kano Kinjo, Keisuke Mine, Yusuke Mori, Mami Ueda, Risa Kaneko, Yuna Kamiya, Taiga Sonoda, Haruka Mimata, Shunsuke Fujita, Takehiro Kawashiri, Daisuke Kobayashi   +11 more
wiley   +1 more source